IONS Earnings & Financial Statements
Ionis Pharmaceuticals, Inc.
$43.96
+$1.26(+2.95%)
36
Overall
40
Value
18
Tech
52
Quality
Market Cap
$7.10B
Volume
740.46K
52W Range
$42.63 - $86.74
Target Price
$79.90
IONS earnings and financial statements: Ionis Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
IONS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $943.71M | $705.14M | $787.65M | $587.37M | $810.46M |
| Cost of revenue | $15.91M | $11.21M | $9.13M | $14.12M | $10.84M |
| Operating income | -$381.68M | -$475.08M | -$353.73M | -$410.19M | -$30.19M |
| EBITDA | -$332.74M | -$414.39M | -$292.48M | -$227.71M | -$5.19M |
| Net income | -$381.39M | -$453.90M | -$366.29M | -$269.72M | -$28.60M |
| EPS (diluted) | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $3.52B | $3.00B | $2.99B | $2.53B | $2.61B |
| Total liabilities | $3.03B | $2.42B | $2.60B | $1.96B | $1.84B |
| Shareholders’ equity | $489.09M | $588.35M | $386.69M | $572.89M | $771.74M |
| Cash and equivalents | $372.26M | $242.08M | $399.27M | $276.47M | $869.19M |
| Long-term debt | $290.50M | $213.73M | $212.71M | $194.91M | $79.14M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$268.58M | -$500.95M | -$307.51M | -$274.37M | $30.80M |
| Capital expenditure | -$57.08M | -$50.34M | -$28.01M | -$20.10M | -$17.90M |
| Free cash flow | -$325.67M | -$551.29M | -$335.52M | -$294.47M | $12.90M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IONS | $43.96 | +3.0% | 740.46K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Ionis Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW